Drug Trial Radar · NCT04404049
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
Last checked: Nov 19, 2026Latest source record: May 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
39
Planned (sponsor's estimate)
Start
Dec 1, 2023
Primary completion
Jun 30, 2024
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- UBP Greater China (Shanghai) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- May 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, randomized, open-label, multi-center, active-controlled study to assess the safety, tolerability, and efficacy of UB-421 administered as an add-on to the standard ART in ART-treated HIV-1 subjects with stably suppressed HIV-1 plasma VL. The study will be conducted at multiple study centers, designated AIDS hospitals in China.
Conditions
- HIV-1-infection
Interventions
UB-421(25 mg/kg) Q2WBiological
Monoclonal antibody by IV infusion plus standard ART
UB-421(25 mg/kg) Q4WBiological
Monoclonal antibody by IV infusion plus standard ART
Primary outcomes
What the sponsor says the trial is designed to measure.
- treatment related TEAEsTime frame: 48Weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.